Author

abenedict

  • Adriana Benedict

    4/25: Boston-Wide Forum on Global Access Licensing of Biomedically Relevant Technologies

    by Adriana Benedict Universities Allied for Essential Medicines (UAEM) Boston-Wide Forum on Global Access Licensing of Biomedically Relevant Technologies Thursday, April 25th, 3-5pm Coffee and refreshments at 2:45pm; reception following the event Harvard Medical School…

    4/25: Boston-Wide Forum on Global Access Licensing of Biomedically Relevant Technologies

  • Adriana Benedict

    If Novartis’s “improved” version of Glivec is not more therapeutically efficacious, why is the Novartis decision such a big deal?

    By Adriana Benedict Last week, Ryan Abbot blogged here about the Novartis case decided last Monday by the Supreme Court of India.  Since then, there have been a broad range of reactions to the case,…

    If Novartis’s “improved” version of Glivec is not more therapeutically efficacious, why is the Novartis decision such a big deal?

  • Adriana Benedict

    Oral Arguments in FTC v. Actavis (SC pay for delay case)

    By Adriana Benedict As Jonathan Darrow notes below, on Monday, the Supreme Court heard oral arguments in Federal Trade Commission (FTC) v. Actavis, the “pay for delay” case questioning whether or not reverse payment settlements…

    Oral Arguments in FTC v. Actavis (SC pay for delay case)

  • Adriana Benedict

    Contrasting Views: Recent Publications on Access to Medicines

    by Adriana Benedict Last week, the World Health Organization (WHO), World Intellectual Property Organization (WIPO) and World Trade Organization (WTO) released a trilateral study on Promoting Access to Medical Technologies and Innovation: Intersections between public…

    Contrasting Views: Recent Publications on Access to Medicines

  • Adriana Benedict

    No Access to Medicines without Access to Research

    by Adriana Benedict In December, I wrote a blog post noting that access to biomedical research is critical not only for informed patient care, but also for the sustainable development of pharmaceutical R&D responsive to…

    No Access to Medicines without Access to Research

  • Adriana Benedict

    A Myriad of Options in the Spirit of the Law

    by Adriana Lee Benedict In a couple days, petitioners in AMP v. USPTO will be filing their brief on the merits following the Supreme Court’s grant of certiorari in late November.  For many, the Supreme…

    A Myriad of Options in the Spirit of the Law

  • Adriana Benedict

    2012 Global Congress on Intellectual Property and the Public Interest

    By Adriana Benedict The 2012 Global Congress on Intellectual Property and the Public Interest has just come to a close in Rio de Janeiro, Brazil.  The conference brought together global leaders in intellectual property-related fields like…

    2012 Global Congress on Intellectual Property and the Public Interest

  • Adriana Benedict

    Open Access to Health Research: Highlights from the NIH Public Access Policy panel

    By Adriana Benedict As of 2008, the NIH Public Access Policy requires “that all investigators funded by the NIH submit or have submitted for them to the National Library of Medicine’s PubMed Central an electronic…

    Open Access to Health Research: Highlights from the NIH Public Access Policy panel

  • Adriana Benedict

    Innovative Approaches to Pharmaceutical Innovation: Alternative R&D Mechanisms

    by Adriana Lee Benedict Earlier this year, the World Health Organization’s Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG) issued a report calling for, inter alia, increased support for innovative pharmaceutical…

    Innovative Approaches to Pharmaceutical Innovation: Alternative R&D Mechanisms